Aldeyra

Yahoo Finance • 11 days ago

Inherited Retinal Disease Market Analysis Report 2025-2035, Featuring Profiles of Novartis, GenSight Biologics, Aldeyra Therapeutics, and Spark Therapeutics

Company Logo The global inherited retinal disease market is poised for significant growth by 2025, driven by increasing prevalence of retinal conditions and advancements in genetic and cell-based therapies. Key diseases include retinitis... Full story

Yahoo Finance • 3 months ago

Alkermes appoints new CFO

* Joshua Reed has been appointed as chief financial officer of Alkermes (NASDAQ:ALKS [https://seekingalpha.com/symbol/ALKS]), effective September 15, 2025. * Reed previously served as CFO of Omega Therapeutics and Aldeyra Therapeutics... Full story

Yahoo Finance • 3 months ago

JonesTrading Lifts Aldeyra Therapeutics, Inc. (ALDX) Price Target to $9

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) is among the best US stocks under $10 to invest in. Catherine Novack, an analyst at JonesTrading, has raised the price target on Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) to $9.00 from $6.00, while r... Full story

Yahoo Finance • 4 months ago

FDA accepts Aldeyra's resubmitted NDA for dry eye disease drug

LEXINGTON, Mass. - Aldeyra Therapeutics, Inc. (NASDAQ:ALDX), whose stock has surged over 26% in the past year according to InvestingPro data, announced Thursday that the U.S. Food and Drug Administration has accepted its resubmitted New Dr... Full story

Yahoo Finance • 5 months ago

Aldeyra resubmits Reproxalap's marketing application to FDA

[Dry Eyes Concept On Wooden Desk] AndreyPopov/iStock via Getty Images Aldeyra Therapeutics (NASDAQ:ALDX [https://seekingalpha.com/symbol/ALDX]) said that it has resubmitted its marketing application to the U.S. FDA for its dry eye treatme... Full story

Yahoo Finance • 5 months ago

Aldeyra resubmits NDA for dry eye disease drug after trial success

LEXINGTON, Mass. - Aldeyra Therapeutics, Inc. (NASDAQ:ALDX), whose stock has surged over 12% in the past week according to InvestingPro data, has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration for topic... Full story

Yahoo Finance • 7 months ago

Bragar Eagel & Squire, P.C. Is Investigating Organon, Aldeyra, Landstar, and ICU Medical and Encourages Investors to Contact the Firm

NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Organon & Co. (NYSE:OGN), Aldeyra Therapeutics, Inc. (NASDAQ:ALDX), La... Full story

Yahoo Finance • 7 months ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aldeyra Therapeutics, Inc. – ALDX

NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) (NASDAQ: ALDX). Such investors are advised to contact Danielle Peyton at n... Full story

Yahoo Finance • 7 months ago

Bragar Eagel & Squire, P.C. Is Investigating RobinHood, Aldeyra, Landstar, and ICU Medical and Encourages Investors to Contact the Firm

NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against RobinHood Markets, Inc. (NASDAQ: HOOD), Aldeyra Therapeutics, Inc. (NA... Full story

Yahoo Finance • 7 months ago

ALDX SECURITIES UPDATE: Aldeyra Therapeutics Investors with Losses may have been affected by Securities Violations – Contact BFA Law (NASDAQ:ALDX)

NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for potential violations of the federal securities laws. If you... Full story

Yahoo Finance • 7 months ago

Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA’s Reproxalap Complete Response Letter – Hagens Berman

SAN FRANCISCO, May 06, 2025 (GLOBE NEWSWIRE) -- On April 3, 2025 investors in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) saw the price of their shares crash over 70% after the company announced that it received a Complete Response Letter... Full story

Yahoo Finance • 7 months ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX

NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) (NASDAQ: ALDX).  Such investors are advised to contact Danielle Peyton at... Full story

Yahoo Finance • 7 months ago

ALDX SECURITIES ALERT: Lose Money on Aldeyra Therapeutics, Inc.? Contact BFA Law about Securities Investigation (NASDAQ:ALDX)

NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for potential violations of the federal securities laws. If you... Full story

Yahoo Finance • 7 months ago

ALDX INQUIRY NOTICE: Aldeyra Therapeutics (NASDAQ:ALDX) Investors may have been affected by Securities Violations -- Contact BFA Law

NEW YORK, May 03, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for potential violations of the federal securities laws. If you... Full story

Yahoo Finance • 7 months ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) (NASDAQ: ALDX).  Such investors are advised to contact Danielle Peyton... Full story

Yahoo Finance • 7 months ago

Bragar Eagel & Squire, P.C. Is Investigating TechTarget and Aldeyra and Encourages Investors to Contact the Firm

NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against TechTarget, Inc. (NASDAQ:TTGT) and Aldeyra Therapeutics, Inc. (NASDA... Full story

Yahoo Finance • 7 months ago

ALDX SHAREHOLDER REVIEW: Aldeyra Therapeutics (NASDAQ:ALDX) is being Investigated after 75% Stock Drop – Investors are Urged to Contact BFA Law

NEW YORK, April 27, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for potential violations of the federal securities laws. If yo... Full story

Yahoo Finance • 7 months ago

LEGAL NOTICE: Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Investors are Notified of the Pending Securities Investigation - Contact BFA Law

NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for potential violations of the federal securities laws. If yo... Full story

Yahoo Finance • 7 months ago

ALDX LEGAL REMINDER: Did Aldeyra Therapeutics, Inc. Commit Securities Violations? Contact BFA Law (NASDAQ:ALDX)

NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for potential violations of the federal securities laws. If yo... Full story

Yahoo Finance • 7 months ago

ALDX INVESTOR NEWS: Aldeyra Therapeutics, Inc. Investors may be able to Recover Losses in Class Action Investigation -- Contact BFA Law (NASDAQ:ALDX)

NEW YORK, April 19, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for potential violations of the federal securities laws. If yo... Full story